Results

Total Results: 1,192 records

Showing results for "short".

1. App-F2-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - N N Randomized Weight Gain: n Weight Gain: N N Randomized Gould, 2020 Fair LBP TCA Desipramine 12 Short … NR NR NR NR NR NR NR 5 38 38 NR NR NR NR NR NR NR 0 38 38 Gould, 2020 Fair LBP Placebo Placebo 12 Short … NR NR NR 1 33 33 NR NR NR NR NR NR NR 0 33 33 Hudson, 2021 Good Knee OA TCA Nortriptyline 25 mg 14 Short … NR NR 86 99 102 Sweating 31 99 102 58 99 102 NR NR NR Hudson, 2021 Good Knee OA Placebo Placebo 14 Short … NR NR NR NR NR NR Kivitz, 2013 Fair LBP NSAID Naproxen 1000 mg/day 16 Short 10 295 5 295 9 295 295

2. App-F2-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - N N Randomized Weight Gain: n Weight Gain: N N Randomized Gould, 2020 Fair LBP TCA Desipramine 12 Short … NR NR NR NR NR NR NR 5 38 38 NR NR NR NR NR NR NR 0 38 38 Gould, 2020 Fair LBP Placebo Placebo 12 Short … NR NR NR 1 33 33 NR NR NR NR NR NR NR 0 33 33 Hudson, 2021 Good Knee OA TCA Nortriptyline 25 mg 14 Short … NR NR 86 99 102 Sweating 31 99 102 58 99 102 NR NR NR Hudson, 2021 Good Knee OA Placebo Placebo 14 Short … Gain: N N Randomized Abdelhafeez, 2019 Fair Chronic pelvic pain GBP Gabapentin 900-2700 mg/day 24 Short

3. App-F2-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - N N Randomized Weight Gain: n Weight Gain: N N Randomized Gould, 2020 Fair LBP TCA Desipramine 12 Short … NR NR NR NR NR NR NR 5 38 38 NR NR NR NR NR NR NR 0 38 38 Gould, 2020 Fair LBP Placebo Placebo 12 Short … NR NR NR 1 33 33 NR NR NR NR NR NR NR 0 33 33 Hudson, 2021 Good Knee OA TCA Nortriptyline 25 mg 14 Short … NR NR 86 99 102 Sweating 31 99 102 58 99 102 NR NR NR Hudson, 2021 Good Knee OA Placebo Placebo 14 Short … NR NR NR NR NR NR NR Somnolence 30 170 170 71 170 170 NR NR NR Zhang, 2021 Fair FM PGB Placebo 16 Short

4. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update - Evidence Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/noninvasive-nonpharm-pain-summary.pdf
   April 01, 2020 - function and a moderate improvement for short-term pain (SOE: low). … Short-term (4 trials) or intermediate- term (1 trial) function, short-term (5 trials) or intermediate-term … Function or pain at short or intermediate term (1 trial, SOE: low for all). – Massage. … Function at short term (1 trial, SOE: low). … term (3 trials) and intermediate term (2 trials) (SOE: low for short and intermediate term).

5. App-F1-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - 43 43 43 Khasbage, 2021 Good NPP (DPN) SNRI Duloxetine 60 mg/day ≥50% decrease on VAS 12 Short 43 43 … 83 167 167 Langford, 2013 Good NPP (MS) Placebo Placebo ≥30% improvement on NRS 14 Short 77 172 172 … Lee, 2020 Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥30% improvement on DPRS 12 Short 93 130 176 Lee … Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥50% improvement on DPRS 12 Short 62 130 176 Lee, 2020 Fair … 16 Short 62 230 230 Kivitz, 2013 Fair LBP NSAID Naproxen ≥50% reduction on NRS from baseline 16 Short

6. Nonopioid Pharmacologic Treatments for Chronic Pain: Appendix F2 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-apf2_0.xlsx
   January 01, 2018 - AE n N N Randomized Specific AE n N N Randomized Arnold, 2004 Fair FM SNRI Duloxetine 120 mg/d 12 Short … 18 104 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR Arnold, 2004 Fair FM Placebo Placebo 12 Short … NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR Arnold, 2005 Fair FM SNRI Duloxetine 60 mg/d 12 Short … 118 NR Somnolence 6 118 NR Hyperhidrosis 6 118 NR Arnold, 2005 Fair FM SNRI Duloxetine 120 mg/d 12 Short … 5 120 NR Hyperhidrosis 1 120 NR Arnold, 2010a Fair FM SNRI Duloxetine 60 to 120 mg/d (mean NR) 12 Short

7. App-F1-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - 43 43 43 Khasbage, 2021 Good NPP (DPN) SNRI Duloxetine 60 mg/day ≥50% decrease on VAS 12 Short 43 43 … 83 167 167 Langford, 2013 Good NPP (MS) Placebo Placebo ≥30% improvement on NRS 14 Short 77 172 172 … Lee, 2020 Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥30% improvement on DPRS 12 Short 93 130 176 Lee … , 2020 Fair NPP (DPN/PHN) PGB/GBP Pregabalin IR ≥30% improvement on DPRS 12 Short 91 131 176 Lee, 2020 … Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥50% improvement on DPRS 12 Short 62 130 176 Lee, 2020 Fair

8. App-F1-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - 83 167 167 Langford, 2013 Good NPP (MS) Placebo Placebo ≥30% improvement on NRS 14 Short 77 172 172 … Lee, 2020 Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥30% improvement on DPRS 12 Short 93 130 176 Lee … , 2020 Fair NPP (DPN/PHN) PGB/GBP Pregabalin IR ≥30% improvement on DPRS 12 Short 91 131 176 Lee, 2020 … Fair NPP (DPN/PHN) PGB/GBP Pregabalin CR ≥50% improvement on DPRS 12 Short 62 130 176 Lee, 2020 Fair … NPP (DPN/PHN) PGB/GBP Pregabalin IR ≥50% improvement on DPRS 12 Short 59 131 176 NPP_Function Table

9. Evidence-Summary-CER-209-Noninvasive-Nonpharmacological-Treatment-For-Chronic-Pain (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-209-evidence-summary-non-pharma-chronic-pain.pdf
   June 01, 2018 - Acupuncture • Acupuncture was associated with slightly greater effects on short-term function than … • There was no statistically significant difference between yoga versus exercise in short-term or … • One trial found no evidence of differences between qigong versus exercise in short-term function … (SOE: low for short term; moderate for intermediate term). … (SOE: low for short and intermediate term).

10. A Prioritized Research Agenda for Using the Harmonized Outcome Measures in the Support Patient-Centered Outcomes Research in Depression (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/prioritized-research-agenda.pdf
    October 01, 2021 - Patient-centered outcomes research (short-term) 2. … Patient-centered outcomes research (short-term) 2. … Patient-centered outcomes research (short-term) 3. … Patient-centered outcomes research (short-term) 4. … Patient-centered outcomes research (short-term) 2.

11. CER 229 Evidence Summary: Opioid Treatments for Chronic Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-229-opioid-treatments-chronic-pain-evidence-summary.pdf
    April 01, 2020 - • At short-term followup, evidence showed no differences between opioids versus nonopioid medications … followup (12 trials, N=2886) at short-term followup (SOE: moderate) … long- vs. short- acting formulations of the same opioid administered at similar doses (SOE: low) … might be associated with a small mean short- term improvement in SF-36 mental health status. … Effects of opioids on short-term outcomes were generally consistent across opioid types.

12. Nonopioid Pharmacologic Treatments for Chronic Pain: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-summary.pdf
    April 01, 2020 - Thirty-two trials evaluated harms in short-term treatment with anticonvulsants. … Seventy-nine trials evaluated harms of NSAID treatment in the short term. … Topical diclofenac showed small improvement in pain in the short term. … Acetaminophen did not improve pain significantly in the short or intermediate term. … Term Effect Size SOE Function Short Term Effect Size SOE QoL Short Term Effect Size SOE Neuropathic

13. Appendix-E-Evidence-Tables-E1-E4 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Evidence-Tables-E1-E4_0.xlsx
    May 29, 2025 - 6 doses with stable dosing for further 3 weeks 5.4 sprays/day Placebo 5.3 sprays/day NA NA NA NA 5 Short … 0.08 mg CBD) Placebo (olive oil) Mean dose at postintervention evaluation was 4.3 drops NA NA NA NA 8 Short … mg 3 times/day; days 11 to 52: 8 mg 3/day Range: 15 to 24 mg/day Placebo 3 tablets/day NA NA NA NA 7 Short … day, crossover to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short … titrated to max 12 sprays per day 8 sprays (range 3 to 12 sprays) Placebo 11 sprays NA NA NA NA 4 Short

14. Slide 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cf_deliberativemethodswebinar_goalsetting.pdf
    May 29, 2025 - Community Problem Solving 3 Lay out the Pathway to the Goals Activity Outputs Outcomes Short-Term … based on the activities, outputs, and short- term outcomes Expected changes in policy, culture … , conditions, etc. based on the activities, outputs, short- and mid-term outcomes 4 Getting

15. Cannabis-App-F1-F4-Tables-Surveillance-Report-2 0 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f1-f4-tables-surveillance-report-2_0_0.xlsx
    May 29, 2025 - 6 doses with stable dosing for further 3 weeks 5.4 sprays/day Placebo 5.3 sprays/day NA NA NA NA 5 Short … 0.08 mg CBD) Placebo (olive oil) Mean dose at postintervention evaluation was 4.3 drops NA NA NA NA 8 Short … mg 3 times/day; days 11 to 52: 8 mg 3/day Range: 15 to 24 mg/day Placebo 3 tablets/day NA NA NA NA 7 Short … day, crossover to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short … titrated to max 12 sprays per day 8 sprays (range 3 to 12 sprays) Placebo 11 sprays NA NA NA NA 4 Short

16. Systematic Review on Noninvasive Nonpharmacological Treatment for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-2-noninvasive-nonpharma.pdf
    April 01, 2022 - UC, AC, or placebo Function, short term Small improvement SOE: Moderate 10 RCTs (N=940) *2 … exercise Function, short term No evidence at short term 1 fair-quality RCT (N=34)7 No effect … term No evidence 1 fair-quality RCT (N=73)10 No effect No effect SOE: Low Pain, short … sham, UC, AC Function, short term Small improvement SOE: Low 3 RCTs (N=704) *1 fair-quality … RCT (N=155)11 No effect No change in conclusions Pain, short term No effect SOE: Low 3

17. Cer-250-Cannabis-2025-Surv-Rep-Update-Tables-E1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-tables-e1-4.xlsx
    January 01, 2025 - to affected area daily for 8 weeks + 500 mg acetaminophen tablet daily "10 drops" Placebo NR NA NA 8 Short … 6 doses with stable dosing for further 3 weeks 5.4 sprays/day Placebo 5.3 sprays/day NA NA NA NA 5 Short … 0.08 mg CBD) Placebo (olive oil) Mean dose at postintervention evaluation was 4.3 drops NA NA NA NA 8 Short … mg 3 times/day; days 11 to 52: 8 mg 3/day Range: 15 to 24 mg/day Placebo 3 tablets/day NA NA NA NA 7 Short … Max dose six drops three times daily Placebo NA 16 Short NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR

18. Cannabis-2022-Update-Surv-Rep-1-App-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
    January 01, 2022 - 6 doses with stable dosing for further 3 weeks 5.4 sprays/day Placebo 5.3 sprays/day NA NA NA NA 5 Short … 0.08 mg CBD) Placebo (olive oil) Mean dose at postintervention evaluation was 4.3 drops NA NA NA NA 8 Short … mg 3 times/day; days 11 to 52: 8 mg 3/day Range: 15 to 24 mg/day Placebo 3 tablets/day NA NA NA NA 7 Short … day, crossover to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short … titrated to max 12 sprays per day 8 sprays (range 3 to 12 sprays) Placebo 11 sprays NA NA NA NA 4 Short

19. Cer-250-Cannabis-Tables-E1-E4-2022-Update 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-e1-e4-2022-update_0.xlsx
    January 01, 2022 - 6 doses with stable dosing for further 3 weeks 5.4 sprays/day Placebo 5.3 sprays/day NA NA NA NA 5 Short … 0.08 mg CBD) Placebo (olive oil) Mean dose at postintervention evaluation was 4.3 drops NA NA NA NA 8 Short … mg 3 times/day; days 11 to 52: 8 mg 3/day Range: 15 to 24 mg/day Placebo 3 tablets/day NA NA NA NA 7 Short … day, crossover to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short … titrated to max 12 sprays per day 8 sprays (range 3 to 12 sprays) Placebo 11 sprays NA NA NA NA 4 Short

20. PEPTIC ULCER #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - Short bowel syndrome. [internet]. … Available: http://digestive.niddk.nih.gov/ddiseases/pubs/short bowel/. 2. Yazbeck R. … A new treatment for patients with short-bowel syndrome. … Short bowel syndrome. In: PubMed Health [database online]. … Short bowel syndrome (SBS). [internet].